5 either nacubactam or zidebactam, or either BLI alone. A total of 100 µL of a log phase culture 7 0 containing 1 × 10 4 to 5 × 10 4 CFU was added to each well except the negative control well 7 1 (media only). Plates were incubated at 30°C for 3 days for Middlebrook 7H9 broth. The MIC was 7 2 defined as the lowest concentration of β -lactam that prevented growth as observed by the 7 3 naked eye. MIC 50 and MIC 90 were defined as the MIC at which at least 50% and at least 90%, 7 4 respectively, of the clinical MABC isolates were inhibited. DST was repeated to confirm the MIC 7 5 against M. abscessus ATCC 19977. 7 6 7 7
Results

8
Initially, we studied the effect of β -lactams in presence and absence of nacubactam and 7 9 zidebactam against M. abscessus ATCC 19977. Both BLIs improved the activity of 8 0 carbapenems and some cephalosporins ( Table 1 ). The potentiating effects were greatest with 8 1 tebipenem, ertapenem, cefuroxime, ceftaroline and, to a lesser extent, meropenem. However, 8 2 nacubactam was generally slightly more effective than zidebactam and it uniquely potentiated 8 3 the effects of amoxicillin. Nacubactam at 8 µg/mL resulted in two-fold lower MICs compared to 4 8 4 µg/mL for some β -lactams, while zidebactam results were similar irrespective of the 8 5 concentration tested. Specifically, nacubactam at 8 µg/mL and zidebactam at 4-8 µg/mL 8 6 improved the activity of their partner β -lactams, meropenem and cefepime by eight-fold and two-8 7 fold, respectively. As previously observed with avibactam and relebactam, MICs of cefoxitin 8 8 remained unchanged in the presence of nacubactam and zidebactam, reflecting the stability of 8 9 cefoxitin to MABC β -lactamase activity (17). The MICs of nacubactam and zidebactam against 9 0 M. abscessus 19977 was >256 µg/mL, suggesting that their potentiation of β -lactam activity 9 1 were due to β -lactamase inhibition rather than any intrinsic anti-bacterial effects. 9 2 6
We chose 8 µg/mL for nacubactam and 4 µg/mL for zidebactam as fixed concentrations to 9 3 screen against the clinical isolates. On average, the clinical isolates were more resistant than M. 9 4 abscessus 19977. However, both BLIs improved the activity of selected β -lactams ( lactams, meropenem and cefepime by 8-fold and 2-fold, respectively, as well as those of the 9 7 carbapenems, several cephalosporins (ceftaroline, cefuroxime and cefdinir) and, in the case of 9 8 nacubactam, amoxicillin, consistent with their effects against ATCC 19977. 9 9
Against the clinical isolates, the addition of 8 µg/mL nacubactam reduced the meropenem MIC 50 1 0 0 from 32 µg/mL to 4 µg/mL, thus changing the interpretation from resistant to susceptible, 1 0 1 according to CLSI breakpoints for M. abscessus (albeit using 7H9 broth rather than the CAMHB 1 0 2 media recommended by CLSI, for reasons we explained previously) (10). Indeed, all 28 clinical 1 0 3 isolates had MICs within the susceptible-to-intermediate range when meropenem was combined 1 0 4 with nacubactam. These results are somewhat better than those observed in our previous study 1 0 5 when meropenem was combined with vaborbactam 4 µg/mL (10). In conclusion, this study demonstrates that nacubactam and zidebactam improve the anti-1 2 7 MABC activity of carbapenems, several cephalosporins, and, in the case of nacubactam, 1 2 8 amoxicillin. Specifically, addition of nacubactam lowered meropenem MICs eight-fold, resulting 1 2 9 in all isolates being susceptible or intermediately susceptible by CLSI interpretive criteria for 1 3 0 meropenem. In our previous study (10), the meropenem/vaborbactam combination was not 1 3 1 quite as potent as the meropenem/nacubactam combination studied here against the same 1 3 2
isolates, suggesting that meropenem/nacubactam, if approved, could have an advantage for the 1 3 3 treatment of MABC infections. However, further head-to-head comparisons with larger numbers 1 3 4 of clinical isolates are required before drawing a more confident conclusion. Zidebactam had a 1 3 5 more modest effect on cefepime MICs and cefepime has lower intrinsic activity against MABC 1 3 6 than meropenem. However, emerging evidence suggests that combinations of two 
